A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

Phase 2Active Not RecruitingNCT06577935

Angitia Biopharmaceuticals379 enrolled

Overview

The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.

This Phase 2 dose-finding study will evaluate the safety, tolerability, and efficacy of AGA2118 at a range of dosing regimens in postmenopausal women with low BMD at the lumbar spine, total hip, or femoral neck and no prior history of fragility fractures. This study includes a 12 month blinded treatment phase where participants will be randomized 1:1:1:1:1:1:1 to receive double-blind dosing regimens of AGA2118 or placebo. At Month 12, participants who have completed the double-blind portion of the study will continue on to a 12 month open-label period where they will be re-randomized based on their prior dosing regimen to either continue their current dosing regimen, receive a new dosing regimen, or discontinue treatment and be actively surveilled throughout Months 12 to 24.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

379

Conditions

Postmenopausal Osteoporosis

Interventions

AGA2118DRUG

Subcutaneous injection

PlaceboOTHER

Subcutaneous injection

Eligibility

Sex: FEMALEMin age: 55 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy, ambulatory, postmenopausal women age ≥ 55 to ≤ 80. * BMD T-score of ≤ -2.5 to \> -3.5 at the lumbar spine, total hip, or femoral neck. Exclusion Criteria: * History of vertebral fracture, or fragility fracture of the wrist, humerus, proximal femur, or pelvis. * Vitamin D deficiency. * Known intolerance to calcium or vitamin D supplements. * Untreated hyper- or hypothyroidism. * Current hyper- or hypoparathyroidism. * Elevated transaminases. * Significantly impaired renal function. * Current hypo- or hypercalcemia. * Positive for HIV, hepatitis C virus, or hepatitis B surface antigen. * Malignancy within the last 5 years. * Diagnosis of a familial cancer syndrome or known genetic mutation that increases risk of cancer. * Myocardial infarction or stroke within the past 12 months. * Use of agents affecting bone metabolism.

Locations (23)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Outcomes

Primary Outcomes

Percent change from Baseline to Month 12 in lumbar spine bone mineral density

To determine the effect of treatment with AGA2118 versus placebo at Month 12 on the percent change from Baseline in bone mineral density at the lumbar spine in postmenopausal women with low bone mineral density

Time frame: 12 months

Secondary Outcomes

Percent change from Baseline to Months 3 and 6 in lumbar spine, total hip, femoral neck, and one-third distal radius bone mineral density

To evaluate the effect of treatment with AGA2118 versus placebo at different timepoints on percent change from Baseline in bone mineral density at the lumbar spine, total hip, femoral neck, and one-third distal radius

Time frame: 3 and 6 months

Percent change from Baseline to Month 12 in total hip, femoral neck, and one-third distal radius bone mineral density

Time frame: 12 months

Percent change from Baseline to Months 1, 3, 6, 9, and 12 in P1NP and CTX-1

To evaluate the effect of treatment with AGA2118 versus placebo at different time points on percent change from Baseline in P1NP and CTX-1

Time frame: 1, 3, 6, 9, and 12 months

Incidence of new clinical fractures (vertebral and nonvertebral) between Baseline and Month 12

To evaluate the incidence of new clinical fractures (vertebral and nonvertebral) from Baseline to Month 12

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.